It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
In order toevaluate the influence of the metabolic syndrome (MS) (obesity, hypertension, elevated triglycerides, reduced levels of HDL cholesterol and glucose impairment) on the phenotype of LRRK2 and GBA Parkinson’s disease (PD), and on the prevalence of prodromal features among individuals at risk, we collected, laboratory test results, blood pressure, demographic, cognitive, motor, olfactory and affective information enabling the assessment of each component of MS and the construction of the MDS prodromal probability score. The number of metabolic components and their levels were compared between participants who were separated based on disease state and genetic status. One hundred and four idiopathic PD, 40 LRRK2-PD, 70 GBA-PD, 196 healthy non-carriers, 55 LRRK2-NMC and 97 GBA-NMC participated in this study. PD groups and non manifesting carriers (NMC) did not differ in the number of metabolic components (p = 0.101, p = 0.685, respectively). LRRK2-PD had higher levels of triglycerides (p = 0.015) and higher rates of prediabetes (p = 0.004), while LRRK2-NMC had higher triglyceride levels (p = 0.014). NMC with probability rates for prodromal PD above 50% had higher frequencies of hypertriglyceridemia and prediabetes (p < 0.005, p = 0.023 respectively). While elevated triglycerides and prediabetes were more frequent among LRRK2 carriers, MS does not seem to influence GBA and LRRK2-PD phenotype.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Movement Disorders Unit, Neurological Institute, Tel-Aviv Medical Center, Tel Aviv-Yafo, Israel (GRID:grid.413449.f) (ISNI:0000 0001 0518 6922); Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546); Sagol School of Neuroscience, Tel-Aviv University, Tel Aviv-Yafo, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546)
2 Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546); Department of Internal Medicine “C”, “D”, and “E”, Tel-Aviv Medical Center, Tel Aviv-Yafo, Israel (GRID:grid.413449.f) (ISNI:0000 0001 0518 6922)
3 Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546)
4 Movement Disorders Unit, Neurological Institute, Tel-Aviv Medical Center, Tel Aviv-Yafo, Israel (GRID:grid.413449.f) (ISNI:0000 0001 0518 6922); Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546)
5 Genetic Institute, Tel-Aviv Medical Center, Tel Aviv-Yafo, Israel (GRID:grid.413449.f) (ISNI:0000 0001 0518 6922)
6 Genomic Research Laboratory for Neurodegeneration, Tel-Aviv Medical Center, Tel Aviv-Yafo, Israel (GRID:grid.413449.f) (ISNI:0000 0001 0518 6922)
7 Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546); Neurology department, Meir Hospital, Kfar-Saba, Israel (GRID:grid.415250.7) (ISNI:0000 0001 0325 0791)
8 Biogen Inc, Cambridge, USA (GRID:grid.417832.b) (ISNI:0000 0004 0384 8146); Coeruleus Clinical Sciences LLC, Woodbridge, USA (GRID:grid.417832.b)
9 Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546); Genomic Research Laboratory for Neurodegeneration, Tel-Aviv Medical Center, Tel Aviv-Yafo, Israel (GRID:grid.413449.f) (ISNI:0000 0001 0518 6922)
10 Movement Disorders Unit, Neurological Institute, Tel-Aviv Medical Center, Tel Aviv-Yafo, Israel (GRID:grid.413449.f) (ISNI:0000 0001 0518 6922); Sackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546); Sagol School of Neuroscience, Tel-Aviv University, Tel Aviv-Yafo, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546); Laboratory of Early Markers of Neurodegeneration, Neurological Institute, Tel-Aviv Medical Center, Tel Aviv-Yafo, Israel (GRID:grid.413449.f) (ISNI:0000 0001 0518 6922)




